- Home
- DXYZ vs ORIC Comparison
DXYZ vs ORIC Comparison
Compare DXYZ & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DXYZ | ORIC |
|---|---|---|
| Founded | N/A | 2014 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.0M | 783.0M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DXYZ | ORIC |
|---|---|---|
| Price | $28.62 | $8.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $19.73 |
| AVG Volume (30 Days) | N/A | ★ 1.4M |
| Earning Date | N/A | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $3.90 |
| 52 Week High | N/A | $14.93 |
Technical Indicators
Market Signals| Indicator | DXYZ | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 35.58 |
| Support Level | $30.10 | $7.84 |
| Resistance Level | $32.98 | $8.33 |
| Average True Range (ATR) | 2.11 | 0.42 |
| MACD | -0.58 | 0.10 |
| Stochastic Oscillator | 13.11 | 42.65 |
Price Performance
Historical ComparisonAbout DXYZ Destiny Tech100 Inc.
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.